ライフサイエンスコーパス: a specificity of

1 iodontitis yielded a sensitivity of 0.91 and a specificity of 0.19.

2 individuals with a sensitivity of 0.918 and a specificity of 0.545.

3 5% confidence interval [CI]: 0.57, 0.94) and a specificity of 0.80 (95% CI: 0.66, 0.88).

4 .0 (95% confidence interval [CI], 0.54-1.0), a specificity of 0.83 (95% CI, 0.36-1.0), a negative pre

5 y increased to 0.74 (95% CI, 0.59-0.85) with a specificity of 0.85 (95% CI, 0.77-0.90).

6 nsitivity of 0.78 (95% CI, 0.64 to 0.87) and a specificity of 0.87 (95% CI, 0.75 to 0.93) for DLBCL.

7 ibutions, we found a sensitivity of 0.92 and a specificity of 0.88 for the classification of major de

8 e a sensitivity of 0.70 (95% CI, 0.64-0.77), a specificity of 0.90 (95% CI, 0.84-0.93), a positive li

9 s a sensitivity of 0.69 (95% CI, 0.55-0.81), a specificity of 0.92 (95% CI, 0.86-0.95), a positive li

10 reached a sensitivity of 0.8758/0.9297, and a specificity of 0.9297/0.8758 for arteries/veins, respe

11 95% confidence interval [CI], 0.43-0.80) and a specificity of 0.93 (95% CI, 0.85-0.97).

12 is presented with a sensitivity of 0.52 and a specificity of 0.95.

13 nsitivity of 0.81 (95% CI, 0.72 to 0.89) and a specificity of 0.97 (95% CI, 0.94 to 0.99) for advance

14 tigen portion had a sensitivity of 0.000 and a specificity of 0.983.

15 ibody portion had a sensitivity of 0.994 and a specificity of 0.992.

16 rquartile range [IQR], 0.9808 to 0.9904) and a specificity of 0.9954 (IQR, 0.9954 to 1.0).

17 involvement with a sensitivity of 0.875 and a specificity of 1.

18 tivity of 0.817, 0.967, 0.950, and 0.983 and a specificity of 1.000, 0.880, 1.000, and 0.880, respect

19 d a sensitivity of 96% (23 of 24 lesions) at a specificity of 100% (23 of 23 lesions), yielding signi

20 The assay had a specificity of 100% (95% CI 98.9-100; 339 of 339 contr

21 idence interval [CI], 90.26% to 100.00%) and a specificity of 100% (95% CI, 63.06% to 100.00%) when u

22 th a sensitivity of 67% (95% CI, 43-85%) and a specificity of 100% (95% CI, 78-100%).

23 a sensitivity of 77% (95% CI, 57 to 89) and a specificity of 100% (95% CI, 90 to 100).

24 sensitivity of 95% (95% CI, 83% to 99%) and a specificity of 100% (95% CI, 92% to 100%).

25 ity of 90.91% (95% CI, 78.33% to 97.47%) and a specificity of 100% (95% CI, 93.40% to 100.00%) for th

26 ith a sensitivity of 48% (95% CI, 35-61) and a specificity of 100% (95% CI, 94-100).

27 ity for vCJD of 71.4% (95% CI 47.8-88.7) and a specificity of 100% (95% CIs between 97.8% and 100%).

28 ularity in 21 of 94 lesions (P = .0006), for a specificity of 100% (95% confidence interval [CI]: 84,

29 criteria was 0% (95% CI, 0.0% to 0.5%), with a specificity of 100% (CI, 97% to 100%) and a positive p

30 nd a sensitivity of 75% (CI, 19% to 99%) and a specificity of 100% (CI, 97% to 100%) in the United Ki

31 on (sensitivity of 67% [16 of 24 lesions] at a specificity of 100% [23 of 23 lesions]) (P = .035).

32 ool EIA were 95% and 35%, respectively, with a specificity of 100% for both methods.

33 nd 100% (23/23), respectively, while showing a specificity of 100% for each target.

34 llent; USG showed a sensitivity of 86.7% and a specificity of 100% for full-thickness tears, and a se

35 criterion provided a sensitivity of 78% and a specificity of 100% for the detection of thymic lympho

36 n general, HRCM had a sensitivity of 75% and a specificity of 100% in identifying recurrent or persis

37 e population, a test sensitivity of 96%, and a specificity of 100%, the calculated VE estimates using

38 MTBDR-Plus had a sensitivity of 81.0% and a specificity of 100%, with sensitivities of 44.1% in AF

39 tion and copy number of inserted genes, with a specificity of 100%.

40 detecting surgery-related deaths of 33% and a specificity of 100%.

41 nor plasma specimens tested and demonstrated a specificity of 100%.

42 blood positive, for a sensitivity of 21% and a specificity of 100%.

43 s, corresponding to a sensitivity of 96% and a specificity of 100%.

44 vity of 82%, and 73% after eradication, with a specificity of 100%.

45 IHP assay had a sensitivity of 50 to 80% and a specificity of 100%.

46 -FDHT PET, yielding a sensitivity of 91% and a specificity of 100%; the optimal cutoff was an SUVmax

47 The graded PC had a specificity of 100.0% (95% CI, 90.9%-100.0%), a negati

48 confidence interval [CI], 66.1 to 99.8) and a specificity of 100.0% (95% CI, 98.4 to 100.0).

49 wine IAV-ss) with a sensitivity of 84.9% and a specificity of 100.0%.

50 udy, the Canadian medium-risk rule exhibited a specificity of 12.3% (95% CI: 11.6%-13.1%), while the

51 value of 98.5% (95% CI, 97.6%.6-99.1%), and a specificity of 13.3% (95% CI, 12.6%-14.1%) for TICI.

52 a sensitivity of 99.2% (95% CI 95.4%-100%), a specificity of 20.8% (95% CI 19.2%-22.4%), and a negat

53 a sensitivity of 95.4% (95% CI 93.6%-96.9%), a specificity of 25.5% (95% CI 23.5%-27.5%), and a NPV o

54 a sensitivity of 99.2% (95% CI 95.4%-100%), a specificity of 31.7% (95% CI 29.9%-33.5%), and a NPV o

55 sitivity of 100% (95% CI: 96.7%-100.0%) with a specificity of 32.6% (95% CI: 31.5%-33.6%).

56 11.6%-13.1%), while the NEXUS rule exhibited a specificity of 33.3% (95% CI: 32.3%-34.4%).

57 </=16 mg/mL showed a sensitivity of 87% and a specificity of 36%.

58 a sensitivity of 90.7% (95% CI 88.3%-92.8%), a specificity of 37.9% (95% CI 35.8%-40.1%), and a NPV o

59 ensitivity of 100% (95% CI, 63% to 100%) and a specificity of 40% (95% CI, 25% to 56%).

60 e measures displayed a sensitivity of 95.4%, a specificity of 40.1%, and positive and negative predic

61 /=16%) at baseline had a sensitivity of 88%, a specificity of 46%, and an accuracy of 0.67 (P<0.001)

62 a sensitivity of 89% (95% CI, 84 to 92), and a specificity of 47% (95% CI, 36 to 59).

63 a sensitivity of 88% (95% CI, 83 to 92), and a specificity of 47% (95% CI, 37 to 58).

64 e showed an overall sensitivity of 80.2% and a specificity of 47.1%, with positive and negative predi

65 hese symptoms had a sensitivity of 80.8% and a specificity of 51.2% for identifying a period in which

66 lts, the cobas test showed a sensitivity and a specificity of 51.9 and 86.6%, respectively.

67 5% confidence interval [CI], 84 to 97), with a specificity of 52% (95% CI, 44 to 59).

68 ad a sensitivity of 100% (29 of 29 lesions), a specificity of 53.2% (nine of 17 lesions), and an area

69 confidence interval [CI] = 60.7 to 93.5) and a specificity of 53.3% (95% CI = 37.9 to 68.3) for diagn

70 ensitivity of 73% and 89%, respectively, and a specificity of 56% and 25%, respectively.

71 of 97.3% (95% CI: 92.3%-99.4%) and exhibited a specificity of 58.8% (95% CI: 57.7%-59.9%).

72 ed sensitivity was 94% (95% CI: 73%, 99%) at a specificity of 59% (95% CI: 42%, 74%).

73 The algorithm had a specificity of 61% and a sensitivity of 92%.

74 criteria yielded a sensitivity of 71.4% and a specificity of 62.2%.

75 ADC measurement resulted in a specificity of 63%-64% and 61%-63%, sensitivity of 41%

76 95% confidence interval [CI], 93.6-98.6) and a specificity of 64% (95% CI, 61.6-66.4) for the diagnos

77 [95% confidence interval]) 67% (57-76)% and a specificity of 65% (54-75)%.

78 ) and </=75%TEI had a sensitivity of 98% but a specificity of 66% to predict viability at follow-up.

79 95% confidence interval [CI]: 72%-93%), with a specificity of 67% (95% CI: 45%-84%).

80 l [corrected], with a sensitivity of 83% and a specificity of 67% (area under the curve, 0.75).

81 ith a sensitivity of 79% (95% CI, 64-94) and a specificity of 68% (95% CI, 56-80).

82 63% (95% confidence interval 38% to 84%) and a specificity of 69% (95% confidence interval 41% to 89%

83 dict surgery with a sensitivity of 88.9% and a specificity of 69%.

84 cut-off level of 432 pg/mL on day 1 yielded a specificity of 70% and a sensitivity of 64% for the pr

85 I, 0.666-0.847) and a sensitivity of 78% and a specificity of 70%, 3.51 mg/L was established as the l

86 Spot had an overall sensitivity of 89.8% and a specificity of 70.4%.

87 % to 94.8%) for the detection of >/=CIN2 and a specificity of 70.5% (95% CI, 68.1% to 72.7%).

88 to be detected with a sensitivity of 85% and a specificity of 71%.

89 )cum = 0.343) had a sensitivity of 76.0% and a specificity of 71.4% in the test group.

90 urine samples showed a sensitivity of 96.5%, a specificity of 71.4%, and positive and negative predic

91 n accuracy of 84%, a sensitivity of 92%, and a specificity of 72% for detecting myocardial ischemia a

92 ent (MCC) of 0.59, a sensitivity of 86%, and a specificity of 72% for FS indels.

93 [95% confidence interval]) 54% (44-63)% and a specificity of 73% (63-82)%.

94 ielded a sensitivity of 80% (95% CI: 51-95), a specificity of 74% (95% CI: 57-86), a PPV of 55% (95%

95 , whereas with OCT, a sensitivity of 82% and a specificity of 74% was recorded in the inferior RNFL q

96 tivariate model has a sensitivity of 80% and a specificity of 74%.

97 bnormality, CTP had a sensitivity of 93% and a specificity of 74%.

98 .5 ng/mL provided a sensitivity of 90.4% and a specificity of 74.1%.

99 loon expulsion time with 75% sensitivity and a specificity of 75%.

100 nsitivity of 78.6% (95% CI, 60.5%-89.8%) and a specificity of 75.0% (95% CI, 55.1%-88.0%) for correct

101 redicted death with a sensitivity of 71% and a specificity of 76%.

102 ve delirium with a sensitivity of 71.19% and a specificity of 76.26% (receiver operating analysis, ar

103 s associated with a sensitivity of 75.8% and a specificity of 76.3%.

104 3 (0.72-0.95), with a sensitivity of 85% and a specificity of 77% and was also superior to day 1 sept

105 e a sensitivity of 64% (95% CrI: 55, 73) and a specificity of 78% (95% CrI: 73, 83).

106 hours with a sensitivity of 57% and 70% and a specificity of 78% and 82%, respectively.

107 curacy of 74% (with a sensitivity of 68% and a specificity of 78%).

108 achines and 10-fold cross validation yielded a specificity of 78.8%, and a sensitivity of 92.5%, as w

109 ned with a sensitivity of 78% (39 of 50) and a specificity of 79% (92 of 116).

110 atients with a sensitivity of 76% to 89% and a specificity of 79% to 93%.

111 rse remodeling with a sensitivity of 84% and a specificity of 79%.

112 the AURKA gene copy number in urine yielded a specificity of 79.7% (95% confidence interval [CI] = 7

113 asis, CTP alone had a sensitivity of 79% and a specificity of 80% for the detection of stenosis > or

114 cohort resulted in a sensitivity of 100% and a specificity of 80%.

115 um lytA rtPCR had a sensitivity of 78.1% and a specificity of 80.0%.

116 ensitivity of 80.3% (95% CI: 76.7-83.5%) and a specificity of 80.3% (95% CI: 76.9-83.3%).

117 sensitivity of 66.1% (95% CI 63.2-68.9) and a specificity of 80.6% (79.2-82.0) in the 12 months prec

118 itrary units had a sensitivity of 90.91% and a specificity of 80.60% for disseminated intravascular c

119 hs provided a sensitivity of 64% and 87% and a specificity of 81% and 74% respectively, for successfu

120 RTE showed a sensitivity of 100%, a specificity of 81%, a negative predictive value of 100

121 9, P < .001), with a sensitivity of 100% and a specificity of 81%, indicating that SHAPE may be a use

122 ects without ARVC, for a sensitivity of 91%, a specificity of 82%, a positive predictive value of 83%

123 ons <50 nmol/L with a sensitivity of 61% and a specificity of 82%, whereas these values were 61% and

124 itivity of 71.4% (95% CI 30.3% to 94.9%) and a specificity of 82.0% (95% CI 72.1% to 89.1%) (cell-fre

125 with a sensitivity of 53.7% (42.6-64.3) and a specificity of 82.8% (76.7-86) in the 12 months preced

126 ensitivity of 80% and 55%, respectively, and a specificity of 83% and 63%.

127 the baseline study had a sensitivity of 47%, a specificity of 83%, and an accuracy of 0.65 (P=0.002)

128 rfusion imaging had a sensitivity of 67% and a specificity of 83%.

129 to predict CAV with a sensitivity of 72% and a specificity of 83%.

130 confidence interval [CI], 68.6 to 94.3) and a specificity of 83.6% (95% CI, 74.6 to 92.7) for the di

131 75-83%), and 55% (50-59%), respectively, and a specificity of 84% (81-87%), 64% (59-69%), and 70% (66

132 validation provided a sensitivity of 86% and a specificity of 84% (area under the receiver operating

133 diagnostic of acute cellular rejection with a specificity of 84% and a sensitivity of 90%.

134 etecting myopia and a sensitivity of 41% and a specificity of 84% in detecting hyperopia.

135 ssify the legions with a sensitivity of 96%, a specificity of 84%, and an AUC of 0.97.

136 aft fibrosis with a sensitivity of 93.8% and a specificity of 84.1% (P<0.0001).

137 take) resulted in a sensitivity of 81.3% and a specificity of 84.3%.

138 tivity of 71.4% and 70.4%, respectively, and a specificity of 84.6% and 80.3%, respectively.The respe

139 tivity of 72.9% and 63.2%, respectively, and a specificity of 84.7% and 85.3%, respectively; for ages

140 d a sensitivity of 49% (95% CI, 41%-57%) and a specificity of 85% (95% CI, 81%-89%) for predicting ch

141 nemase activity had a sensitivity of 99% and a specificity of 85%.

142 gnosis of ABMR had a sensitivity of 100% and a specificity of 85%.

143 confidence interval [CI]: 75.4%, 96.7%) and a specificity of 85.0% (95% CI: 74.9%, 91.7%).

144 f HLA-B*13:01 had a sensitivity of 85.5% and a specificity of 85.7% as a predictor of the dapsone hyp

145 sm criteria, with a sensitivity of 88.9% and a specificity of 85.7%, with several metabolites contrib

146 qPCR combined had a sensitivity of 100% and a specificity of 85.7%.

147 gic imaging reached a sensitivity of 82% and a specificity of 86% (accuracy, 83%).

148 This model had a sensitivity of 41%, a specificity of 86%, and a receiver operating character

149 une activation with a sensitivity of 91% and a specificity of 86%.

150 ations (kappa 0.652, SE 0.154, p<0.001) with a specificity of 87% (sensitivity 15%).

151 arted to discriminate from day 3 onward with a specificity of 87% and a sensitivity of 58% for a cut-

152 bapenemase producers (98% sensitivity), with a specificity of 87%.

153 lation failure with a sensitivity of 82% and a specificity of 87%.

154 sh RRMS with a sensitivity of 90.9% and with a specificity of 87.1% against AQP4-ab NMOSD, 95.2% agai

155 at a sensitivity of 97.6% (87.4%-99.9%) and a specificity of 87.5% (47.3%-99.7%).

156 aft fibrosis with a sensitivity of 77.3% and a specificity of 87.5% (P<0.0001).

157 f SCD with a sensitivity of 91% (78-98%) and a specificity of 88% (74-98%).

158 th a sensitivity of 90% (95% CI, 56-100) and a specificity of 88% (95% CI, 68-97).

159 89% (95% confidence interval 67% to 99%) and a specificity of 88% (95% confidence interval 62% to 98%

160 a dominant stricture plus FISH polysomy has a specificity of 88% for CCA.

161 )F-DOPA PET yielded a sensitivity of 93% and a specificity of 88% for the detection of paragangliomas

162 ity for a genetic degranulation disorder and a specificity of 88%.

163 5, 0.91-0.99), with a sensitivity of 93% and a specificity of 88%.

164 participants with a sensitivity of 80.4% and a specificity of 88.0%, a finding that was confirmed usi

165 n the groups with a sensitivity of 90.0% and a specificity of 88.1%.

166 d a sensitivity of 93.1% (27 of 29 lesions), a specificity of 88.2% (15 of 17 lesions), and an area u

167 ed a sensitivity of 100% (29 of 29 lesions), a specificity of 88.2% (16 of 18 lesions), and an area u

168 d a sensitivity of 69.6% (62.1 to 76.4%) and a specificity of 88.4% (82.6 to 92.8%) during days 4 to

169 % (confidence interval [CI], 64% to 95%) and a specificity of 89% (CI, 73% to 97%) in Sierra Leone (n

170 % CI, 0.76-0.96), with a sensitivity of 73%, a specificity of 89%, a negative predictive value of 98%

171 -free outcomes with a sensitivity of 57% and a specificity of 89%.

172 f value of 3.25 ng/mL with a sensitivity and a specificity of 89.3% and 88.5%, respectively.

173 ntially methylated genes in T or OD produced a specificity of 89.4% and a sensitivity of 85.7%.

174 At a specificity of 89.9%, the cardiac arrest risk triage s

175 tration device had a sensitivity of 81.3% at a specificity of 90% (16 bladder cancer patients and 8 h

176 h a sensitivity of 100% (95% CI, 75-100) and a specificity of 90% (95% CI, 70-99).

177 s is predicted with a sensitivity of 84% and a specificity of 90%.

178 rve) of 0.81 with a sensitivity of 48% given a specificity of 90%.

179 a finger/heel stick was done was 61.9%, with a specificity of 90.0%.

180 MAP assay had a sensitivity of 60 to 70% and a specificity of 90.5 to 100%.

181 gital software had a sensitivity of 100% and a specificity of 90.7% with the specificity ranging betw

182 ions was 0.913, with a sensitivity of 91.9%, a specificity of 90.7%, a positive predictive value (PPV

183 FCU yielded a specificity of 90.9% (95% confidence interval, 89.3-92

184 ared with a sensitivity of 38% (18%-62%) and a specificity of 91% (76%-98%) for procalcitonin.

185 n Assessment Method for the ICU demonstrated a specificity of 91% (95% CI, 90-93), sensitivity of 75%

186 83% (95% confidence interval, 0.36-0.99) and a specificity of 91% (95% confidence interval, 0.77-0.97

187 han 0.20 logMAR had a sensitivity of 92% and a specificity of 91% in detecting myopia and a sensitivi

188 lain/HRP showed a sensitivity of 50%/81% and a specificity of 91%/90%.

189 n a test set of 48 samples, for which it had a specificity of 92% (95% CI 81-100) and a sensitivity o

190 d a sensitivity of 100% (95% CI 90-100%) and a specificity of 92% (95% CI 86-95%) for IgG4-TIN.

191 n is predicted with a sensitivity of 95% and a specificity of 92% (area under the curve=0.98, 95% con

192 of>/=2 TIs yielded a sensitivity of 41% and a specificity of 92% for predicting ASD risk status, whe

193 ld be detected with a sensitivity of 99% and a specificity of 92% using a cutoff water content value

194 sensitivity of 93.9% (95% CI, 85.4%-97.6%), a specificity of 92.0% (95% CI, 85.9%-95.6%), a positive

195 000 copies/mL had a sensitivity of 82.2% and a specificity of 92.0% for distinguishing pneumococcal C

196 monstrated a sensitivity of 96.7% (202/209), a specificity of 92.2% (153/166), a positive predictive

197 tivity of 55.0% and 71.7%, respectively, and a specificity of 92.8% and 78.7% respectively; and for a

198 These data showed a sensitivity of 94.6% and a specificity of 92.9% for the above SD OCT features in

199 patients with CD and control subjects showed a specificity of 92.9%, which was higher than that of gl

200 ensitivity of 80% and 93%, respectively, and a specificity of 93% and 93%, respectively.

201 as cut off yielded a sensitivity of 73% and a specificity of 93% with good positive and negative lik

202 This rate resulted in a sensitivity of 94%, a specificity of 93%, a positive predictive value of 89%

203 At a specificity of 93%, our model had a higher sensitivity

204 tient validation, T2-weighted MR imaging had a specificity of 93%-97% and 87%-95%, sensitivity of 32%

205 follows: a sensitivity of 44.0% (80 of 182), a specificity of 93.1% (364 of 391), a positive predicti

206 of 16 patients without malignant lesions for a specificity of 94% (95% CI, 71% to 100%).

207 uence with an overall sensitivity of 91% and a specificity of 94% and (ii) predicts ptRNA-subclasses

208 Both cutoff points correspond with a specificity of 94% and represent sensitivity of 63% fo

209 CT with CT fusion had a sensitivity of 100%, a specificity of 94%, and an accuracy of 96%.

210 ng at age 3 years with a sensitivity of 77%, a specificity of 94%, and an area under the curve (AUC)

211 ivity of 100.0% (95% CI, 98.0 to 100.0%) and a specificity of 94.0% (95% CI, 89.4 to 96.9%).

212 A sensitivity of 94.1% and a specificity of 94.2% were reached, using a cutoff valu

213 At a specificity of 94.3% (4 eyes showed ONH surface depres

214 rol subjects with a sensitivity of 91.1% and a specificity of 94.3%.

215 ase antibodies with a sensitivity of 50% and a specificity of 94.4%.

216 he Direct LPA had a sensitivity of 88.4% and a specificity of 94.6% for M. tuberculosis detection, wi

217 itivity of 94.7% (95% CI, 73.5 to 99.9), and a specificity of 94.8% (95% CI, 88.9 to 97.8).

218 we obtained a sensitivity of 100% (5/5) and a specificity of 95% (58/61), caused by three false-posi

219 set of 36 samples, the RNAseq classifier had a specificity of 95% (84-100) and a sensitivity of 59% (

220 ols with a sensitivity of 88% (84%-95%), and a specificity of 95% (90%-100%).

221 positive PCR test results were found to have a specificity of 95% and a sensitivity of 64% for invasi

222 orithm exploiting these differences achieved a specificity of 95% and a sensitivity of 91% in the tra

223 AROC of 0.983 and a sensitivity of 96.7% at a specificity of 95%.

224 ulin-3 levels had a sensitivity of 96.7% and a specificity of 95.5% at a cutoff value of 52.8 ng of f

225 was similar, with a sensitivity of 98.9% and a specificity of 95.5%.

226 the OPS-ELISA had a sensitivity of 71.6% and a specificity of 95.7% for Thai controls; for U.S. contr

227 ith a sensitivity of 56% (95% CI, 41-70) and a specificity of 96% (95% CI, 86-100).

228 red to as other-organism septicemia), giving a specificity of 96% (95% CI, 86.5 to 99.5%).

229 A score of >/= 4 for day 1 model had a specificity of 96% and sensitivity of 21%, whereas a s

230 V patient sera with a sensitivity of 91% and a specificity of 96% in the test set.

231 symptom onset with a sensitivity of 61% and a specificity of 96% using a cut-off of 0.34ng/ml.

232 howed a sensitivity of 89%, 86%, and 82% and a specificity of 96%, 98%, and 87% in the detection of p

233 and venography had a sensitivity of 92% and a specificity of 96%, but 52% of patients (194 of 370) h

234 The 90DM had a sensitivity of 74% and a specificity of 96%.

235 p, both the Bayesian and the OLS methods had a specificity of 96%.

236 ic precision with a sensitivity of 77.7% and a specificity of 96.1%.

237 sitivity of 99.2% (range, 95.2% to 100%) and a specificity of 96.5% (range, 89.2% to 100%) for identi

238 rion of 1.3 D had a sensitivity of 83.3% and a specificity of 96.5%.

239 y with a sensitivity of 93.5% (58 of 62) and a specificity of 96.6% (258 of 267).

240 confidence interval [CI], 88.2 to 96.2%) and a specificity of 96.7% (95% CI, 93.0 to 98.8%), and PCR-

241 MIP-1alpha had a specificity of 96.8% and a sensitivity of 100%, wherea

242 selection yielded a sensitivity of 72.1% and a specificity of 96.9%.

243 SC)] with a sensitivity of 90% (73-98%) and a specificity of 97% (86-100%).

244 R assay had an overall sensitivity of 42.5%, a specificity of 97%, a positive predictive value of 77%

245 festation of all eight of these features has a specificity of 97%, and a sensitivity of 89% for the p

246 meniscus and the posterior femoral line had a specificity of 97%-100% and a sensitivity of 0%.

247 on of all three had a sensitivity of 99% and a specificity of 97%.

248 us ultrasound had a sensitivity of 88.4% and a specificity of 97.3% in detecting RD as compared with

249 ectional OCTA combined with en face OCTA had a specificity of 97.5% for grader A and 100% for grader

250 6% (95% confidence interval, 96.8-98.4%) and a specificity of 97.6% (95% confidence interval, 96.8-98

251 sitivity of 94.3% (range, 87.5% to 100%) and a specificity of 97.8% (range, 96.1% to 100%) for identi

252 The GeneChip showed a specificity of 97.8% and a sensitivity of 94.8% for de

253 % (95% confidence interval [CI] 55% to 91%), a specificity of 98% (95% CI 93% to 100%), an overall ac

254 , this assay showed a sensitivity of 85% and a specificity of 98% for the detection of MDR strains.

255 T-QuIC analysis had a sensitivity of 91% and a specificity of 98% for the diagnosis of sCJD.

256 rker panel achieved a sensitivity of 85% and a specificity of 98%, with an area under the receiver op

257 predicted MetS with a sensitivity of 91% and a specificity of 98%.

258 set, with an optimal sensitivity of 100% and a specificity of 98%.

259 This represents a sensitivity of 95% and a specificity of 98%.

260 by the CLSI method yielded a sensitivity and a specificity of 98.0 and 96.3%, respectively; there wer

261 th a sensitivity of 99.7% (98.3 to 100%) and a specificity of 98.0% (99.4 to 100%).

262 onstrated a sensitivity of 93.8% to 100% and a specificity of 98.0% to 100% for the identification of

263 credible interval [CrI], 77.4% to 86.7%) and a specificity of 98.1% (95% CrI, 97.2% to 100%) using pa

264 CAMPY test had a sensitivity of 98.5% and a specificity of 98.2%.

265 yielded an overall sensitivity of 97.4% and a specificity of 98.5%.

266 t, this cutoff had a sensitivity of 100% and a specificity of 98.7% for identifying MRSA from among S

267 ckness tears, and a sensitivity of 89.7% and a specificity of 98.8% for partial-thickness tears; obse

268 Subanalysis yielded a specificity of 98.9% (95% CI, 98.3%-99.4%) for Candida

269 ty of 83% (95% confidence interval, 66-93%), a specificity of 99% (95% confidence interval, 95-100%),

270 Adjusting thresholds to yield a specificity of 99%, 97%, or 93% resulted in almost equ

271 urve, IDO activity had a sensitivity of 97%, a specificity of 99%, and positive and negative predicti

272 gistry cases showed a sensitivity of 98% and a specificity of 99%.

273 nce angiography had a sensitivity of 78% and a specificity of 99%.

274 The previously defined biomarker profile had a specificity of 99.0%, a sensitivity of 78.5%, and a po

275 pectra, which has a sensitivity of 95.6% and a specificity of 99.1%, whereas BEAV was significantly l

276 r method achieved a sensitivity of 57.5% and a specificity of 99.2%, while maintaining a low FDR of 5

277 ng had a sensitivity of 97.0% (65 of 67) and a specificity of 99.4% (334 of 336).

278 sitivity of 99.6% (range, 96.4% to 100%) and a specificity of 99.5% (range, 98.0% to 100%) for identi

279 stant profile had a sensitivity of 88.7% and a specificity of 99.5% for the identification of mecC MR

280 sitivity of 98.1% (range, 87.5% to 100%) and a specificity of 99.6% (range, 98.3% to 100%) for identi

281 ombination of the three assays, the RTCA had a specificity of 99.6% and a sensitivity of 87.5% (28 of

282 Direct fluorescent-antibody testing has a specificity of 99.6% but a sensitivity of only 65.0%.

283 esulting in a final sensitivity of 99.0% and a specificity of 99.6% for the detection of GAS in phary

284 was obtained with a sensitivity of 97.9% and a specificity of 99.6%.

285 1% (95% confidence interval, 54.5-59.8%) and a specificity of 99.7% (95% confidence interval, 99.4-10

286 ted with an overall sensitivity of 99.4% and a specificity of 99.7%.

287 2.6% (95% confidence interval, 88.8%-96.4%), a specificity of 99.8% (99.6%-99.9%), and a sensitivity

288 1.1% (95% confidence interval, 86.6%-95.5%), a specificity of 99.8% (99.7%-99.9%), and a sensitivity

289 V Combo assay had a sensitivity of 73.7% and a specificity of 99.8%.

290 ensitivity of 93.6% (95% CI 88.2%-97.0%) and a specificity of 99.9% (95% CI 99.6%-100%).

291 hereas>/=4 TIs yielded a sensitivity of 19%, a specificity of 99.9%, and a positive likelihood ratio

292 f and tetraloop, with restrictocin achieving a specificity of approximately 1000-fold by recognizing

293 entration for skin testing aiming to achieve a specificity of at least 95%.

294 rCor a 14 of 1 kUA/L or greater (adults) had a specificity of greater than 90% and accounted for 83%

295 All methods had a specificity of >90% for CROs, and for CPOs, the specif

296 compared to that of postmortem testing, with a specificity of >93.9%.

297 olics and antioxidant capacities, indicating a specificity of individual phenolic compounds present i

298 otocol, in particular DCE MR imaging, offers a specificity of more than 95% for distinguishing recurr

299 ities of 98.4%-100%, while DNA detection had a specificity of only 77%.

300 This result implies a specificity of TMS at the dendritic level that could i